Who Paid My Doc
Santosh Nair
Hematology & Oncology Orange City, FL Medical Doctor
NPI 1982653713 CMS profile 362879
2776 Enterprise Road, Suite 100, Orange City, FL 32763
General payments
$31,717
Research payments
$16,657
Ownership & investment interest
$0
Research they led as principal investigator
$13,490,231
Through program year 2025, Santosh Nair of Orange City, FL is reported in the CMS Open Payments database as having received $31,717 across 96 general payments and $16,657 in research payments paid to them. Separately, studies naming them as principal investigator received $13,490,231 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $68 | 3 | |
| 2024 | General | $19 | 1 | |
| 2024 | Research | $11,748 | 7 | |
| 2023 | General | $830 | 11 | |
| 2023 | Research | $3,149 | 3 | |
| 2022 | General | $557 | 9 | |
| 2022 | Research | $1,014 | 1 | |
| 2021 | General | $1,210 | 13 | |
| 2021 | Research | $747 | 1 | |
| 2020 | General | $321 | 3 | |
| 2019 | General | $28,712 | 56 |
Beside peers
- Santosh Nair
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Santosh Nair were reported at $68. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Santosh Nair | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $28,712 | $529 | $121–$2,516 | $163 |
| 2020 | $321 | $339 | $82–$2,213 | $114 |
| 2021 | $1,210 | $263 | $49–$1,965 | $132 |
| 2022 | $557 | $416 | $103–$2,395 | $149 |
| 2023 | $830 | $542 | $125–$2,646 | $160 |
| 2024 | $19 | $692 | $141–$3,008 | $164 |
| 2025 | $68 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 61 drugsPart D claims
1,884
Drug cost
$4,383,924
Branded share of claims
47.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lenalidomide | Generic | 43 | $622,352 | |
| Ibrance Palbociclib | Brand | 26 | $401,174 | |
| Calquence Acalabrutinib Maleate | Brand | 20 | $307,449 | |
| Sprycel Dasatinib | Brand | 17 | $306,937 | |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | Brand | 29 | $306,440 | |
| Revlimid Lenalidomide | Brand | 15 | $306,251 | |
| Ninlaro Ixazomib Citrate | Brand | 22 | $271,416 | |
| Mvasi Bevacizumab-Awwb | Brand | 44 | $268,323 | |
| Pomalyst Pomalidomide | Brand | 12 | $264,899 | |
| Jakafi Ruxolitinib Phosphate | Brand | 15 | $243,598 |
The 10 drugs with the highest cost, of 61 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 135 billing codesPaid by Medicare
$1,710,345
Medicare patients
418
Services billed
126,227
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Chronic kidney disease | 49% | |
| Cancer | 49% | |
| Diabetes | 41% | |
| Ischemic heart disease | 40% | |
| COPD | 37% | |
| Heart failure | 29% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 11 | 8,600 | $383,727 |
| Injection, denosumab, 1 mg J0897 | Office | 16 | 4,801 | $98,934 |
| Injection, ferric carboxymaltose, 1 mg J1439 | Office | 24 | 34,500 | $29,943 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 | Office | 17 | 9,699 | $2,857 |
| Injection, iron sucrose, 1 mg J1756 | Office | 12 | 8,008 | $1,443 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 23 | 816 | $583 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 37 | 3,250 | $335 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 24 | 1,700 | $154 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 23 | 140 | $92 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 26 | 78 | $73 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| OPDIVO |
|
$19 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
108 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Florida
Martin Dietrich
Hematology & Oncology · Rockledge, FL
Mark Socinski
Hematology & Oncology · Orlando, FL
Tarek Mekhail
Hematology & Oncology · Orlando, FL
Edgardo Santos
Hematology & Oncology · Fort Lauderdale, FL
Daniel Landau
Hematology & Oncology · Orlando, FL
Wassim McHayleh
Hematology & Oncology · Altamonte Springs, FL
Related records
Hematology & Oncology in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.